Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC):: CALGB 80203 preliminary results.

被引：0
|
作者：
Venook, A.
Niedzwiecki, D.
Hollis, D.
Sutherland, S.
Goldberg, R.
Alberts, S.
Benson, A.
Wade, J.
Schilsky, R.
Mayer, R.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] CALGB Stat Ctr, Durham, NC USA
[3] Univ N Carolina, Chapel Hill, NC USA
[4] Mayo Clin, Rochester, MN USA
[5] Northwestern Univ, Chicago, IL 60611 USA
[6] Cent Illinois CCOP, Decatur, IL USA
[7] Univ Chicago, Chicago, IL 60637 USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3509
引用
收藏
页码：148S / 148S
页数：1
相关论文
共 50 条
  • [21] Addition of oxaliplatin (Eloxatine(R), LOHP) to the same leucovorin (LV) and 5 fluorouracil (5fU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report
    Andre, T
    Bensmaine, MA
    Louvet, C
    Lucas, V
    Beerblock, K
    Desseigne, F
    Francois, E
    Merrouche, Y
    Bouche, O
    Morvan, F
    Carola, E
    deGramont, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 738 - 738
  • [22] ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/III rectal cancer receiving either pre or postoperative radiation (RT)/FU.
    Benson, A. B.
    Catalan, P.
    Meropol, N. J.
    Giantonio, B. J.
    Sigurdson, E. R.
    Martenson, J. A.
    Whitehead, R. P.
    Sinicrope, F.
    Mayer, R. J.
    O'Dwyer, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 152S - 152S
  • [23] A multicenter phase II study of irinotecan (CPT) and 5-fluarouracil (5FU)/I-lucovorin (I-LV) in patients with metastatic colorectal cancer: Interim results.
    Fujishima, H
    Uchino, K
    Miyanaga, O
    Ueda, A
    Miyazaki, K
    Ariyama, H
    Baba, E
    Mitsugi, K
    Harada, M
    Nakano, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 286S - 286S
  • [24] Oxaliplatin/5FU/LV in stage II and III Colon Cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial
    de Gramont, Aimery
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Marceau-Suissa, Jeanne
    Andre, Thierry
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 73
  • [25] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [26] A phase I study of bortezomib in combination with 5FU/LV plus oxaliplatin in patients (pts) with advanced colorectal cancer (CRC): EORTC 16029
    Lacombe, D. A.
    Caponigro, F.
    Anthoney, A.
    Bauer, J.
    Govaerts, A.
    Milano, A.
    Marreaud, S.
    Twelves, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Ciprotti, M.
    Donati, S.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
  • [28] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
    Falcone, A.
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Amoroso, D.
    Puglisi, M.
    Fea, E.
    Brunetti, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
    Masi, G.
    Loupakis, F.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Vasile, E.
    Cialo, A.
    Cavaciocchi, D.
    Di Leo, A.
    Puglisi, M.
    Ciprotti, M.
    Amoroso, D.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [30] FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis
    Falcone, A.
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Cupini, S.
    Mancini, M.
    Granetto, C.
    Ribecco, A.
    Andreuccetti, M.
    Brunetti, I. M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 348 - 348
12345